Insider Trading Alert - IPXL, ALOG And EA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 22, 2014, 122 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $90.00 to $13,547,000.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Hsu Larry, who is Director at Impax Laboratories, sold 3,800 shares at $26.53 on May 22, 2014. Following this transaction, the Director owned 459,568 shares meaning that the stake was reduced by 0.82% with the 3,800-share transaction.

The shares most recently traded at $27.66, up $1.13, or 4.07% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 228,235
  • 12-Week # shares sold: 232,235
  • 24-Week # shares sold: 235,235

The average volume for Impax Laboratories has been 774,400 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 8.31% year-to-date as of the close of trading on Thursday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2649.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Analogic (ALOG) - FREE Research Report

Levitz Michael L, who is Sr. VP-CFO and Treasurer at Analogic, sold 666 shares at $75.23 on May 22, 2014. Following this transaction, the Sr. VP-CFO and Treasurer owned 4,633 shares meaning that the stake was reduced by 12.57% with the 666-share transaction.

The shares most recently traded at $76.66, up $1.43, or 1.87% since the insider transaction. Historical insider transactions for Analogic go as follows:

  • 4-Week # shares sold: 2,017
  • 12-Week # shares sold: 9,368
  • 24-Week # shares sold: 13,642

The average volume for Analogic has been 121,600 shares per day over the past 30 days. Analogic has a market cap of $948.0 million and is part of the health care sector and health services industry. Shares are down 14.18% year-to-date as of the close of trading on Thursday.

Analogic Corporation, a technology company, designs, manufactures, and sells medical imaging and security systems and subsystems to original equipment manufacturers and end users in the healthcare and airport security markets worldwide. The stock currently has a dividend yield of 0.52%. The company has a P/E ratio of 29.6. Currently, there are 2 analysts who rate Analogic a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALOG - FREE

TheStreet Quant Ratings rates Analogic as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Analogic Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Electronic Arts (EA) - FREE Research Report

Soderlund Patrick, who is EVP EA Games at Electronic Arts, sold 120,000 shares at $34.65 on May 22, 2014. Following this transaction, the EVP EA Games owned 52,500 shares meaning that the stake was reduced by 69.57% with the 120,000-share transaction.

The shares most recently traded at $34.83, up $0.18, or 0.51% since the insider transaction. Historical insider transactions for Electronic Arts go as follows:

  • 4-Week # shares sold: 229,331
  • 12-Week # shares sold: 229,331
  • 24-Week # shares sold: 269,331

The average volume for Electronic Arts has been 4.7 million shares per day over the past 30 days. Electronic Arts has a market cap of $10.7 billion and is part of the technology sector and computer software & services industry. Shares are up 50.7% year-to-date as of the close of trading on Thursday.

Electronic Arts Inc. develops, markets, publishes, and distributes game software content and services for video game consoles, personal computers, mobile phones, tablets and electronic readers, and the Internet. The company has a P/E ratio of 1153.3. Currently, there are 12 analysts who rate Electronic Arts a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EA - FREE

TheStreet Quant Ratings rates Electronic Arts as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Electronic Arts Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Impax Shares Jump on Merger Buzz

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue